Loading...
•
Dec 31, 2022
Corbus Pharmaceuticals Q4 2022 Earnings Report
Corbus Pharmaceuticals reported financial results for the fourth quarter of 2022 and provided a corporate update.
Key Takeaways
Corbus Pharmaceuticals reported a net loss of $10.9 million for the fourth quarter of 2022. The company's cash and investments on hand are expected to fund operations through the second quarter of 2024.
Expanded precision oncology pipeline with licensing of CRB-701, a clinical-stage Nectin-4 antibody drug conjugate (ADC) from CSPC Pharmaceutical Group.
CRB-601 anti-αvβ8 mAb program scheduled for IND submission in the second half of 2023.
CRB-601 continues to demonstrate compelling pre-clinical monotherapy and combination data with anti-PD-1.
Dr. Yong Ben, a distinguished oncology researcher, joined the Corbus Board of Directors.
Corbus Pharmaceuticals
Corbus Pharmaceuticals
Forward Guidance
Corbus Pharmaceuticals expects its cash and investments to fund operations through the second quarter of 2024.